Myrto Kastrisiou

We don’t have enough information about this author to calculate their statistics. If you think this is an error let us know.
Learn More
Immune checkpoint blockade including programmed cell death 1 pathway inhibition with agents such as nivolumab is gaining ground in a wide array of malignancies, so far demonstrating significantly improved survival rates even in metastatic, often multiply pretreated settings. Although targeted in nature and generally well-tolerated compared with conventional(More)
  • 1